Optic neuroretinitis in association with BCNU and procarbazine therapy
- 1 January 1978
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 4 (1) , 43-48
- https://doi.org/10.1002/mpo.2950040108
Abstract
A 53-year-old man with multiple myeloma and plasma cell leukemia developed severe, acute bilateral optic neuroretinitis 8 days after chemotherapy with BCNU, procarbazine, cyclophosphamide, and prednisolone. He showed some return of function over the following 6 weeks before his death. Both BCNU and procarbazine are known to cross the blood-brain barrier. Procarbazine is known to interfere with neurological function. BCNU has been reported to transiently interfere with vision and, although this patient had highly morbid disease, the onset of optic neuroretinitis 8 days after combination therapy with these 2 drugs raises the possibility that one or both in combination may have been the cause of the optic neuropathy.Keywords
This publication has 15 references indexed in Scilit:
- Optic Neuropathy Presumably Caused by Vincristine TherapyAmerican Journal of Ophthalmology, 1976
- Combination Therapy for MyelomatosisBMJ, 1974
- Drugs Five Years LaterAnnals of Internal Medicine, 1974
- Neurotoxicity of Commonly Used Antineoplastic AgentsNew England Journal of Medicine, 1974
- Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNUCancer, 1974
- Combination chemotherapy for multiple myelomaCancer, 1972
- Treatment for Multiple MyelomaJAMA, 1969
- Effect of Intravitreous Vincristine Sulfate on the Rabbit RetinaAmerican Journal of Ophthalmology, 1968
- The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animalsClinical Pharmacology & Therapeutics, 1967
- Retinal Hemorrhages After TransfusionAmerican Journal of Ophthalmology, 1939